Search research articles
Contact Us
Filters
Showing results (61-70 of 174) with videos related to
Page
of 18
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Janice Smith, Catherine J Mummery, Jeffrey L Cummings, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Alzheimer'S Research & Therapy
|
September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)
Stephen Salloway, Lee A Honigberg, William Cho, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
April 22, 2026
Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup
Ellis S van Etten, Simin Mahinrad, Joshua D Grill, et al.
Archives of Neurology
|
August 16, 2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
Vladimir Coric, Christopher H van Dyck, Stephen Salloway, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
August 25, 2021
Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
Jennifer Ngolab, Michael Donohue, Alison Belsha, et al.
Nature Communications
|
September 10, 2021
Accelerated functional brain aging in pre-clinical familial Alzheimer's disease
Julie Gonneaud, Alex T Baria, Alexa Pichet Binette, et al.
Annals of Neurology
|
July 18, 2018
Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease
Yen Ying Lim, Jason Hassenstab, Alison Goate, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Brain : a Journal of Neurology
|
April 23, 2019
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia
Michael J Pontecorvo, Michael D Devous, Ian Kennedy, et al.
Page
of 18
Search research articles
Search
Showing results (61-70 of 174) with videos related to
Sort By:
Page
of 18
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
December 26, 2025
Drug Development
Janice Smith, Catherine J Mummery, Jeffrey L Cummings, et al.
The Journal of Prevention of Alzheimer'S Disease
|
July 6, 2025
The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Alzheimer'S Research & Therapy
|
September 21, 2018
Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)
Stephen Salloway, Lee A Honigberg, William Cho, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
April 22, 2026
Amyloid-related imaging abnormalities (ARIA) in anti-amyloid therapies for Alzheimer's disease: An update from the Alzheimer's Association ARIA workgroup
Ellis S van Etten, Simin Mahinrad, Joshua D Grill, et al.
Archives of Neurology
|
August 16, 2012
Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease
Vladimir Coric, Christopher H van Dyck, Stephen Salloway, et al.
Alzheimer'S & Dementia (Amsterdam, Netherlands)
|
August 25, 2021
Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
Jennifer Ngolab, Michael Donohue, Alison Belsha, et al.
Nature Communications
|
September 10, 2021
Accelerated functional brain aging in pre-clinical familial Alzheimer's disease
Julie Gonneaud, Alex T Baria, Alexa Pichet Binette, et al.
Annals of Neurology
|
July 18, 2018
Effect of BDNFVal66Met on disease markers in dominantly inherited Alzheimer's disease
Yen Ying Lim, Jason Hassenstab, Alison Goate, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|
April 2, 2025
Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction
Hong Wang, Emel Serap Monkul Nery, Paul Ardayfio, et al.
Brain : a Journal of Neurology
|
April 23, 2019
A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia
Michael J Pontecorvo, Michael D Devous, Ian Kennedy, et al.
Page
of 18